HP 228

Known as: HP-228 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2007
0119952007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Melanocortinergic agents are currently being investigated for a possible therapeutic role in male and female sexual dysfunction… (More)
Is this relevant?
2002
2002
The presence of nitric oxide (NO) synthase (NOS) in hypothalamic structures which control the activity of the pituitary… (More)
Is this relevant?
1999
1999
HP-228 is a cytokine regulating agent from Trega Biosciences (formerly Houghten Pharmaceuticals). It is in phase II trials for… (More)
Is this relevant?
1998
1998
It has been recently demonstrated that nitric oxide (NO), a free radical gas which may act as neurotransmitter in the brain, can… (More)
Is this relevant?
1998
1998
HP 228 is a synthetic heptapeptide analog of alpha-MSH that attenuates the production and release of inflammatory cytokines. The… (More)
Is this relevant?
1997
1997
We determined the binding affinities of the MSH analogues MSH-B, HP-228 and 153N-6 and of the enkephalin analogue GHRP-6 on a… (More)
Is this relevant?
1995
1995
alpha-Melanocyte stimulating hormone has been shown to prevent endotoxin shock. A heptapeptide analog (HP-228) has recently been… (More)
Is this relevant?